[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69824670D1 - TCF-II für Vorbeugung und/oder Behandlung von strahlungsinduzierter Störungen - Google Patents

TCF-II für Vorbeugung und/oder Behandlung von strahlungsinduzierter Störungen

Info

Publication number
DE69824670D1
DE69824670D1 DE69824670T DE69824670T DE69824670D1 DE 69824670 D1 DE69824670 D1 DE 69824670D1 DE 69824670 T DE69824670 T DE 69824670T DE 69824670 T DE69824670 T DE 69824670T DE 69824670 D1 DE69824670 D1 DE 69824670D1
Authority
DE
Germany
Prior art keywords
tcf
prevention
radiation
treatment
induced disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69824670T
Other languages
English (en)
Other versions
DE69824670T2 (de
Inventor
Yoshio Arai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas Pharmaceuticals Inc Sunnyvale Calif Us
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69824670D1 publication Critical patent/DE69824670D1/de
Publication of DE69824670T2 publication Critical patent/DE69824670T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69824670T 1997-07-14 1998-07-09 Verwendung von Tumor-Cytotoxic-Faktor-II (TCF-II) zur Herstellung eines Medikaments zur Verhinderung und/oder Behandlung von strahlungsinduzierten Krankheiten Expired - Fee Related DE69824670T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18838497 1997-07-14
JP9188384A JPH1129493A (ja) 1997-07-14 1997-07-14 放射線障害予防及び／又は治療剤

Publications (2)

Publication Number Publication Date
DE69824670D1 true DE69824670D1 (de) 2004-07-29
DE69824670T2 DE69824670T2 (de) 2004-12-09

Family

ID=16222690

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69824670T Expired - Fee Related DE69824670T2 (de) 1997-07-14 1998-07-09 Verwendung von Tumor-Cytotoxic-Faktor-II (TCF-II) zur Herstellung eines Medikaments zur Verhinderung und/oder Behandlung von strahlungsinduzierten Krankheiten

Country Status (11)

Country Link
US (1) US5998370A (de)
EP (1) EP0891778B1 (de)
JP (1) JPH1129493A (de)
KR (1) KR100564353B1 (de)
AT (1) ATE269714T1 (de)
AU (1) AU732053B2 (de)
CA (1) CA2242559A1 (de)
DE (1) DE69824670T2 (de)
DK (1) DK0891778T3 (de)
ES (1) ES2219810T3 (de)
ZA (1) ZA986090B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3699482B2 (ja) * 1994-12-27 2005-09-28 第一製薬株式会社 Ｔｃｆ変異体
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ES2274567T3 (es) 1997-03-14 2007-05-16 Daiichi Pharmaceutical Co., Ltd. Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
ATE428438T1 (de) * 1992-07-16 2009-05-15 Daiichi Sankyo Co Ltd Tcf-ii enthaltende medizinische zusammensetzung
EP0653211B1 (de) * 1992-07-16 2001-10-17 Snow Brand Milk Products Co., Ltd. Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil
WO1994006456A1 (en) * 1992-09-16 1994-03-31 Genentech, Inc. Protection against liver damage by hgf
JPH08176007A (ja) * 1994-12-27 1996-07-09 Snow Brand Milk Prod Co Ltd 脂質代謝異常治療剤
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ES2274567T3 (es) * 1997-03-14 2007-05-16 Daiichi Pharmaceutical Co., Ltd. Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.

Also Published As

Publication number Publication date
KR19990013676A (ko) 1999-02-25
EP0891778B1 (de) 2004-06-23
EP0891778A2 (de) 1999-01-20
DE69824670T2 (de) 2004-12-09
EP0891778A3 (de) 2000-01-26
ATE269714T1 (de) 2004-07-15
AU7417498A (en) 1999-01-21
US5998370A (en) 1999-12-07
KR100564353B1 (ko) 2006-09-18
AU732053B2 (en) 2001-04-12
ZA986090B (en) 1999-04-20
ES2219810T3 (es) 2004-12-01
CA2242559A1 (en) 1999-01-14
JPH1129493A (ja) 1999-02-02
DK0891778T3 (da) 2004-08-09

Similar Documents

Publication Publication Date Title
ATE201138T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE231724T1 (de) Kombinationstherapie für die behandlung von psychosen
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
HU912359D0 (en) The use of flupirtine active agents for treating muscle-tension
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
DE69526390D1 (de) Kugelförmige Aktivkohle zur Behandlung von Stoma-peripherer Entzündung
ATE226947T1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1- dioxiden, zusammensetzung und deren verwendung
DE69523654D1 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE212548T1 (de) Behandlung und prophylaxe von pankreatitis
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
ITMI920955A1 (it) Idrogeli di tipo polietereammidoamminico come materiali eparinizzabili
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DE69824670D1 (de) TCF-II für Vorbeugung und/oder Behandlung von strahlungsinduzierter Störungen
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
DE3582935D1 (de) Mittel zur behandlung von erkrankungen der venen und des analbereichs.
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
DE69418931D1 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ATLAS PHARMACEUTICALS, INC., SUNNYVALE, CALIF., US

8339 Ceased/non-payment of the annual fee